-
SIRION Biotech Achieves ISO-9001:2015 Certification
SIRION Biotech GmbH is proud to announce our achievement of ISO 9001:2015 certification by DEKRA. ISO 9001 is the worlds most widely recognized standard for a quality management system (QMS). It enables companies to operate more effectively on several different levels, including the ability to focus on customer requirements and constantly finding ways in which to improve and become resilient and sustainable. This ISO 9001:2015 certification reinforces SIRION’s ability to exceed the quality expectations and requirements of our customers. "We are proud of our commitment to serving the scientific community, in particular cell and gene therapy developers, with the highest quality viral vectors" said Dieter Lingelbach, Chief Operations Officer at…
-
Webinar: Entwicklung von Lentiviralen Vektoren für die ex vivo and in vivo Gentherapie
SIRION Biotech, das führende deutsche Unternehmen für Virale Vektoren, präsentiert am 17. November 2021 ab 14.00 (GMT) ein Webinar zur Optimierung des Designs Lentiviraler Vektoren. Die Optimierung des Designs eines lentiviralen Konstrukts in einer frühen Entwicklungsphase ist die Basis für eine erfolgreiche Gentherapie. Das Design des lentiviralen Backbones und der therapeutischen Gen-Kassette beeinflusst sowohl die Sicherheit des Vektors als auch die Produzierbarkeit der Partikel, sowie deren Qualität und Wirksamkeit. Daher wird durch die Optimierung dieser Parameter auch das Sicherheitsprofil und die Effizienz zukünftiger ex vivo and in vivo Gentherapien weiter verbessert. Bisher wurde die Sicherheit von mehr als 25 lentiviralen Backbones in mehr als 200 klinischen Studien getestet. In diesem…
-
Webinar: Developing Lentiviral Vectors for ex vivo and in vivo Gene Therapy
SIRION Biotech, the leading German viral vector company, will present a Webinar on November 17 at 2 PM GMT discussing optimizing lentivirus vector design for improved quality and safety Optimizing the safety of lentiviral vectors has been one of the main focal points of lentiviral vector development. Likewise, the design of the lentiviral backbone and the therapeutic payload cassette can influence the manufacturability of the particles, for example their quality and potency features. Optimizing those features will further improve the safety and efficacy profile of future ex vivo and in vivo gene therapies. To date the safety of over 25 lentivirus backbones has been tested in more than 200 clinical…
-
SIRION Biotech Granted CIR accreditation by French Ministry of Higher Education, Research and Innovation
The French Ministry of Higher Education, Research and Innovation have granted SIRION Biotech a 3-year CIR (Crédit Impôt Recherche) accreditation lasting until end of 2023. As a result, SIRION Biotech GmbH is now on a list of experts accessible on the Ministry website, and companies based in France that work with us can deduct part of the research funds spent at SIRION Biotech from their taxes. This accreditation is the result of SIRION’s drive to improve support for clients in France and Worldwide, enabling them to go one step closer to developing cutting edge therapies with efficient viral vector technologies. “It is a great achievement for us in France, a…
